Form 4: Revance Therapeutics Executive Reports Stock Award Vesting

Dwight Moxie, CLO & GC of Revance Therapeutics, reports the vesting of performance-based restricted stock units (PSUs) on February 29, 2024.

Summary

• Dwight Moxie, the Chief Legal Officer & General Counsel of Revance Therapeutics, filed a Form 4 on March 4, 2024.
• The form reports a transaction that occurred on February 29, 2024, where 15,143 shares of common stock were acquired due to the vesting of performance-based restricted stock units (PSUs).
• These PSUs were granted on January 31, 2023, and vest over a three-year period based on the achievement of revenue goals.
• The Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on the achievement of a revenue goal, measured from January 1, 2023, through December 31, 2023.
• The vesting is subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024.
• Following the reported transaction, Moxie directly owns 149,209 shares of Revance Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document indicates that the company has met certain revenue goals, which is a positive sign. The vesting of PSUs is a standard practice and doesn't necessarily indicate a major shift in the company's outlook, but the achievement of goals is a positive indicator.

Positives

• The vesting of PSUs indicates that Revance Therapeutics achieved certain revenue goals, as certified by the Compensation Committee.
• Dwight Moxie's continued service through the vesting date of March 15, 2024, suggests stability in the company's leadership.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of PSUs tied to revenue goals suggests an expectation of continued revenue generation.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It reflects the company's compensation strategy to incentivize executives based on performance metrics like revenue growth.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• Companies like Allergan (now AbbVie) and Evolus also utilize equity-based incentives to align executive compensation with company performance.
• The specific revenue goals and vesting schedules vary depending on the company's size, stage of development, and strategic objectives.

Stakeholder Impact

• The vesting of PSUs can positively impact shareholder confidence as it aligns executive compensation with company performance.
• Employees may be motivated by the achievement of revenue goals and the potential for future equity-based compensation.

Key Dates

Keywords

Revance Therapeutics, Form 4, PSU, Dwight Moxie, Vesting, Revenue Goals, Compensation Committee, RVNC, Stock Award